Namath Drafts New Team to Fight Osteoarthritis; Ex-Jet QB Joins Forces with Patients, Families and Doctors

Apr 20, 2001, 01:00 ET from Boehringer Ingelheim

    NEW YORK, April 20 /PRNewswire Interactive News Release/ -- While 31 NFL
 teams draft their new players for the upcoming season, just a few blocks away,
 Hall of Fame quarterback Joe Namath is drafting his own team to fight
 osteoarthritis, the most common form of arthritis.  Namath, along with Elliot
 Pellman, M.D., a rheumatologist and Chairman of the Medical Department of the
 New York Jets and Medical Director of the NY Islanders, will be speaking with
 hundreds of New York area doctors and osteoarthritis patients on management
 and treatment options for managing the disease.  Namath's draft kicks off at
 the Grand Hyatt New York on Sunday April 22 at 12:30 pm.
     "I've always believed in being proactive about my health," says Namath,
 the former New York Jets star, who has suffered from osteoarthritis for more
 than 30 years.  "With the help of my doctors I've always tried to follow a
 solid gameplan that includes a combination of exercise, diet, relaxation and
 medication.  Now I want to share what I've learned with my fellow
 osteoarthritis sufferers about options to alleviate the symptoms of this
 painful disease."
     In the past year Joe has teamed up with Boehringer Ingelheim and Abbott
 Laboratories, marketers of the anti-inflammatory drug MOBIC(R) (meloxicam) in
 an effort to help patients become as proactive as he is in their
 osteoarthritis care.
     MOBIC(R) is a non-steroidal anti-inflammatory drug (NSAID) that relieves
 the signs and symptoms of osteoarthritis. The third of three recently approved
 NSAIDs in the US, after Celebrex(R)* (celecoxib) and Vioxx(R)** (rofexocib),
 MOBIC has been available in the U.S. since April 2000, and has been used for
 several years by more than 30 million patients in 100 countries worldwide.
 MOBIC also costs about 20 percent less than Celebrex and Vioxx.
     "I always encourage people with osteoarthritis to actively seek treatment,
 because there is a lot you can do to gain relief." said Dr. Pellman, who is
 also past president of the NFL Physicians Society.  "In addition to exercise
 and weight reduction, medications indicated for the treatment of
 osteoarthritis are good options that physicians should consider based on the
 individual patient."
     Joe Namath was first diagnosed with osteoarthritis in his knees, and now
 suffers from the disease in his thumbs and spine.  His condition is likely due
 to a combination of trauma experienced while playing football, a hereditary
 link to his mother having osteoarthritis, and simply growing older.  Namath
 has been active with the Arthritis Foundation and many other initiatives to
 increase awareness of the disease and inform patients about their options.
     "Over the years, I've learned how the pain of osteoarthritis can take
 control of your life, but that it doesn't have to," says Namath. "So now, on
 NFL Draft Day, I'm drafting my own team to pull people together and develop a
 plan to help alleviate the symptoms that may limit the way you move. After
 all, we need to be able to keep up with our children and grandchildren,
 participate in our favorite activities, and most of all, continue to enjoy
 life."
     Approximately 40 million Americans suffer from arthritis -- 20 million of
 whom have osteoarthritis, which is characterized by joint pain, swelling and
 stiffness, as well as a reduction in mobility.
     MOBIC(R) is contraindicated in patients who have experienced asthma,
 itching or allergic type reactions after taking aspirin or other nonsteroidal
 anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactic-like
 reactions to NSAIDs have been reported in such patients. As with all NSAIDs,
 serious GI toxicity such as inflammation, bleeding, ulceration, and
 perforation of the stomach, small intestine, or large intestine can occur at
 any time, with or without symptoms.
     To register for Sunday's osteoarthritis seminar at the Grand Hyatt New
 York, log onto http://www.NamathKnows.com.  Please see attached brief
 prescribing information.  For additional information regarding MOBIC,
 including full prescribing information, please visit
 http://www.mobictablet.com.
 
     About Boehringer Ingelheim
     The Boehringer Ingelheim group of companies ("Boehringer Ingelheim"), with
 headquarters in Ingelheim (Germany) is one of the 20 leading pharmaceutical
 firms in the world and reported revenues of almost US $5.4 billion in 1999.
     Boehringer Ingelheim has worldwide some 140 affiliated companies. The
 focus is on the human pharmaceutical as well as on the animal health business.
 The human pharmaceutical business, which is responsible for 92% of sales,
 includes mainly ethical pharmaceuticals and consumer healthcare but also
 products for industrial customers (chemicals and biopharmaceuticals).
     Substantial research and development, production, and distribution
 facilities are located around the globe. In 1999 Boehringer Ingelheim spent US
 $882.8 million on R&D, equivalent to 16% of total sales.
     For more information, please visit http://www.boehringer-ingelheim.com.
 
     *   CELEBREX is a registered trademark of G.D. Searle & Co.
     **  VIOXX is a registered trademark of Merck & Company, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X53368124
 
 

SOURCE Boehringer Ingelheim
    NEW YORK, April 20 /PRNewswire Interactive News Release/ -- While 31 NFL
 teams draft their new players for the upcoming season, just a few blocks away,
 Hall of Fame quarterback Joe Namath is drafting his own team to fight
 osteoarthritis, the most common form of arthritis.  Namath, along with Elliot
 Pellman, M.D., a rheumatologist and Chairman of the Medical Department of the
 New York Jets and Medical Director of the NY Islanders, will be speaking with
 hundreds of New York area doctors and osteoarthritis patients on management
 and treatment options for managing the disease.  Namath's draft kicks off at
 the Grand Hyatt New York on Sunday April 22 at 12:30 pm.
     "I've always believed in being proactive about my health," says Namath,
 the former New York Jets star, who has suffered from osteoarthritis for more
 than 30 years.  "With the help of my doctors I've always tried to follow a
 solid gameplan that includes a combination of exercise, diet, relaxation and
 medication.  Now I want to share what I've learned with my fellow
 osteoarthritis sufferers about options to alleviate the symptoms of this
 painful disease."
     In the past year Joe has teamed up with Boehringer Ingelheim and Abbott
 Laboratories, marketers of the anti-inflammatory drug MOBIC(R) (meloxicam) in
 an effort to help patients become as proactive as he is in their
 osteoarthritis care.
     MOBIC(R) is a non-steroidal anti-inflammatory drug (NSAID) that relieves
 the signs and symptoms of osteoarthritis. The third of three recently approved
 NSAIDs in the US, after Celebrex(R)* (celecoxib) and Vioxx(R)** (rofexocib),
 MOBIC has been available in the U.S. since April 2000, and has been used for
 several years by more than 30 million patients in 100 countries worldwide.
 MOBIC also costs about 20 percent less than Celebrex and Vioxx.
     "I always encourage people with osteoarthritis to actively seek treatment,
 because there is a lot you can do to gain relief." said Dr. Pellman, who is
 also past president of the NFL Physicians Society.  "In addition to exercise
 and weight reduction, medications indicated for the treatment of
 osteoarthritis are good options that physicians should consider based on the
 individual patient."
     Joe Namath was first diagnosed with osteoarthritis in his knees, and now
 suffers from the disease in his thumbs and spine.  His condition is likely due
 to a combination of trauma experienced while playing football, a hereditary
 link to his mother having osteoarthritis, and simply growing older.  Namath
 has been active with the Arthritis Foundation and many other initiatives to
 increase awareness of the disease and inform patients about their options.
     "Over the years, I've learned how the pain of osteoarthritis can take
 control of your life, but that it doesn't have to," says Namath. "So now, on
 NFL Draft Day, I'm drafting my own team to pull people together and develop a
 plan to help alleviate the symptoms that may limit the way you move. After
 all, we need to be able to keep up with our children and grandchildren,
 participate in our favorite activities, and most of all, continue to enjoy
 life."
     Approximately 40 million Americans suffer from arthritis -- 20 million of
 whom have osteoarthritis, which is characterized by joint pain, swelling and
 stiffness, as well as a reduction in mobility.
     MOBIC(R) is contraindicated in patients who have experienced asthma,
 itching or allergic type reactions after taking aspirin or other nonsteroidal
 anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactic-like
 reactions to NSAIDs have been reported in such patients. As with all NSAIDs,
 serious GI toxicity such as inflammation, bleeding, ulceration, and
 perforation of the stomach, small intestine, or large intestine can occur at
 any time, with or without symptoms.
     To register for Sunday's osteoarthritis seminar at the Grand Hyatt New
 York, log onto http://www.NamathKnows.com.  Please see attached brief
 prescribing information.  For additional information regarding MOBIC,
 including full prescribing information, please visit
 http://www.mobictablet.com.
 
     About Boehringer Ingelheim
     The Boehringer Ingelheim group of companies ("Boehringer Ingelheim"), with
 headquarters in Ingelheim (Germany) is one of the 20 leading pharmaceutical
 firms in the world and reported revenues of almost US $5.4 billion in 1999.
     Boehringer Ingelheim has worldwide some 140 affiliated companies. The
 focus is on the human pharmaceutical as well as on the animal health business.
 The human pharmaceutical business, which is responsible for 92% of sales,
 includes mainly ethical pharmaceuticals and consumer healthcare but also
 products for industrial customers (chemicals and biopharmaceuticals).
     Substantial research and development, production, and distribution
 facilities are located around the globe. In 1999 Boehringer Ingelheim spent US
 $882.8 million on R&D, equivalent to 16% of total sales.
     For more information, please visit http://www.boehringer-ingelheim.com.
 
     *   CELEBREX is a registered trademark of G.D. Searle & Co.
     **  VIOXX is a registered trademark of Merck & Company, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X53368124
 
 SOURCE  Boehringer Ingelheim